The diabetes epidemic affects over half a billion people worldwide, reducing quality of life and increasing mortality, yet there is no cure for this debilitating disease. Current treatments manage the consequences of the disease, rather than fixing the underlying causes. NeogeniCo will use an innovative live cell screening approach to develop first-in-class medicines to promote regeneration of pancreatic beta cells, restoring insulin levels and long-term stable glucose control, revolutionising the treatment of diabetes.